Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

BACKGROUND: Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M(pro)) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS: We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908851/
https://www.ncbi.nlm.nih.gov/pubmed/35172054
http://dx.doi.org/10.1056/NEJMoa2118542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908851/
https://www.ncbi.nlm.nih.gov/pubmed/35172054
http://dx.doi.org/10.1056/NEJMoa2118542

Ejemplares similares